Eric Sullivan

Eric Sullivan currently serves as the Chief Financial Officer at Convergent Therapeutics, Inc. and holds a position on the Board of Directors as Chair of the Audit & Risk Committee and a member of the Remuneration & Nomination Committee at Chimeric Therapeutics. Previously, Eric Sullivan was the Chief Financial Officer at TCR² Therapeutics Inc. until its acquisition by Adaptimmune in June 2023, and served in various executive finance roles including Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics and Senior Vice President of Finance at Gemini Therapeutics. Eric Sullivan's earlier experience includes senior finance positions at Oncorus, bluebird bio, and Merrimack, along with a background as an Audit Manager at PwC. Education was completed at Bentley University.